# EDGAR Filing Document

**Accession Number:** 0001558569
**File Stem:** 0001213900-26-013265
**Filing Date:** 2026-2
**Character Count:** 16009
**Document Hash:** 633c2a3f9634129a27302cb6f379e9dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-013265.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001213900-26-013265

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260206

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iSpecimen Inc.
- **CENTRAL INDEX KEY:** 0001558569
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 270480143
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40501
- **FILM NUMBER:** 26607580

**BUSINESS ADDRESS:**
- **STREET 1:** 8 CABOT ROAD
- **STREET 2:** SUITE 1800
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 08101
- **BUSINESS PHONE:** 781-301-6700

**MAIL ADDRESS:**
- **STREET 1:** 8 CABOT ROAD
- **STREET 2:** SUITE 1800
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 08101

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 6, 2026**

**iSpecimen Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40501** | **27-0480143** |
| **(State or other jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

**8 Cabot Road, Suite 1800 Woburn, MA 01801**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (781) 301-6700**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.0001 per share** | **ISPC** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On February 6, 2026, iSpecimen Inc. (the "Company") issued two press releases.

The second press release highlights recent operational achievements demonstrating the strength and responsiveness of the Company's site network in supporting customer research, including rapid influenza specimen procurement. A copy of this press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated February 6, 2026 (Milestone 2 Announcement)](ea027523001ex99-1_ispecimen.htm) |
| 99.2 | [Press Release dated February 6, 2026 (Operational Achievements Announcement)](ea027523001ex99-2_ispecimen.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 6, 2026

---

| | | |
|:---|:---|:---|
| iSPECIMEN INC. | iSPECIMEN INC. | iSPECIMEN INC. |
| By: | /s/ Katharyn Field | /s/ Katharyn Field |
|  | Name: | Katharyn Field |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete**

**Live Production Marketplace Now Available**

Woburn, MA - February 6, 2026: iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.

Chief Executive Officer Ms. Katie Field commented, "This Milestone 2 achievement demonstrates end-to-end system integration, legacy data migration, and activation of a production-ready SalesStack marketplace. We are pleased this will deliver operational continuity and scalable growth for our customers and vendors alike."

Key achievements of the Milestone 2 phase include:

End-to-End System Integration Connected the new SalesStack marketplace to core internal systems, enabling seamless data flow across customer, supplier, and transaction services.

Legacy Data Migration Successfully migrated all historical user, order, and supplier data from the legacy marketplace into the new SalesStack platform.

Production Marketplace Launch Activated the new platform for live use, now available at: Production: https://mp.ispecimen.com

Core Feature Enablement Delivered essential marketplace functionality required for full operational workflows, including order processing, user management, and supplier connectivity.

Enhanced AI-Driven Matching (customer requests and supplier inventories) In line with industry efforts to leverage AI for demand-supply matching, the marketplace now supports AI-assisted matching to more efficiently connect customer requests with available supplier inventories.

Ms. Field continued, "Milestone 2 validates our approach to a connected, AI-informed marketplace. By unifying data and automating core workflows, we're delivering tangible value to customers and suppliers while laying the groundwork for rapid growth."

The Company noted business benefits of this second stage:

Operational Continuity & Stability: The new platform is fully connected to internal systems, enabling live, end-to-end marketplace operations and reducing manual handoffs.

Cost Optimization: As part of the legacy system sunset process, the company will begin downsizing infrastructure supporting the old marketplace, significantly reducing AWS operating expenses.

Improved Scalability & Performance: The new architecture enables faster feature delivery, improved system reliability, and the ability to scale with customer demand.

Foundation for Revenue Growth: With system integration and live marketplace activation complete, iSpecimen is positioned to accelerate supplier onboarding, pricing automation, and new customer acquisition in subsequent phases.

Next steps of the Salestack roll out include expanding supplier onboarding and pricing automation to shorten time-to-market for new suppliers and to enable dynamic, price-competitive listings. We will roll out AI-driven match capabilities at scale to improve precision in connecting customer requests with supplier inventories, reducing manual intervention and accelerating order fulfillment. We will continue the sunset of legacy infrastructure, migrating workloads and data to the SalesStack platform while ensuring uninterrupted service, security, and compliance throughout the transition. Finally, the Company intends to prepare for Milestone 3 by planning additional marketplace features, broader geographic rollout, and deeper integrations with partner ecosystems to drive growth, resilience, and a more seamless buyer-supplier experience.

**About iSpecimen Inc.**

iSpecimen Inc. (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

**Forward Looking Statements**

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

**For further information, please contact:**

info@ispecimen.com

## Exhibit 99.2

**Exhibit 99.2**

**iSpecimen Achieves Rapid Procurement Milestone for Influenza Research**

**Lexington, MA — February 6, 2026** — iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network.

Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected **500 influenza swab samples in just a few weeks** to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the specimens have led to **continued engagement with the customer in future respiratory sampling needs**.

In addition to respiratory specimens, iSpecimen continues to **consistently maintain supply of cerebrospinal fluid (CSF)** to support ongoing customer studies. The company is also experiencing **increased interest from clients seeking support across a broader range of specimen types**, including **FFPE and fresh frozen (FF) tissue**, reflecting growing demand for reliable and diverse biospecimen sourcing.

Customer feedback continues to reinforce iSpecimen's commitment to quality and transparency. One recent customer shared:

 

*"We were very excited upon receiving the urine specimens from iSpecimen and have begun to review all the information we received about the 20 samples. I must say that we are very impressed with their quality, and their extensive documentation."*

The customer also indicated their intent to **mention iSpecimen as the sample source in public discussions and publications**, underscoring confidence in both specimen quality and accompanying documentation.

These accomplishments highlight iSpecimen's ongoing commitment to providing timely access to well-documented biospecimens that support critical research and scientific advancement.

**About iSpecimen Inc.**

iSpecimen Inc. (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

**Forward Looking Statements**

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

**For further information, please contact:**

info@ispecimen.com